A Phase 1b Study of Ivonescimab, a Programmed Cell Death Protein-1 and Vascular Endothelial Growth Factor Bispecific Antibody, as First- or Second-Line Therapy for Advanced or Metastatic Immunotherapy-Naive NSCLC

Lei Wang, Yongzhong Luo, Shengxiang Ren, Zhihong Zhang, Anwen Xiong, Chunxia Su, Jin Zhou, Xinmin Yu, Yanping Hu, Xiaodong Zhang, Xiaorong Dong, Shuyan Meng, Fengying Wu, Xiaoming Hou, Yuanrong Dai, Weifeng Song, Baiyong Li, Zhongmin Maxwell Wang, Xia Yu, Caicun Zhou